Christine Yang, Iris Feng, Paul Kurlansky, Kathryn Fidlow, Dana A Mullin, Melana Yuzefpolskaya, Paolo C Colombo, Gabriel Sayer, Nir Uriel, Yuji Kaku, Justin Fried, Koji Takeda
{"title":"心源性休克急诊医疗转运静脉动脉体外生命支持的效果。","authors":"Christine Yang, Iris Feng, Paul Kurlansky, Kathryn Fidlow, Dana A Mullin, Melana Yuzefpolskaya, Paolo C Colombo, Gabriel Sayer, Nir Uriel, Yuji Kaku, Justin Fried, Koji Takeda","doi":"10.1177/02676591251331952","DOIUrl":null,"url":null,"abstract":"<p><p>IntroductionVeno-arterial extracorporeal life support (V-A ECLS) can be utilized to transport cardiogenic shock patients from a regional to a tertiary center. Mobile extracorporeal membrane oxygenation (ECMO) may be life-saving for critically ill patients to bridge to transplant or a higher level of care.MethodsThis study is a retrospective review of adult patients placed on V-A ECMO for cardiogenic shock between 2018 and 2022. Indications and outcomes were compared between patients who were cannulated at referring hospitals and transported via ambulance and those who were placed on VA-ECLS at our institution.Results547 patients with V-A ECMO placed due to cardiogenic shock were included. 94 patients were transported from referring hospitals, while 453 were placed on V-A ECMO at our institution. All were safely transported. In-hospital mortality was significantly higher in transport patients (49.1% vs 59.5%, <i>p</i> = .042). Transport patients had significantly higher rates of acute kidney injury requiring dialysis (27.8% vs 39.4%, <i>p</i>-value = .035) and cerebrovascular accident (6.2% vs 12.8%, <i>p</i>-value = .026). Kaplan-Meier curves showed 6-month survival was significantly lower in transport group (48.5% vs 37.3%, <i>p</i> = .021). Multivariate analysis demonstrated ECMO indication of AMI (OR 1.43, <i>p</i>-value = .037), ECPR (OR 2.45, <i>p</i>-value <.001), and history of COPD (OR 1.55, <i>p</i>-value = .014) were predictors of mortality within 12 months. Notably ECMO transport was not a significant risk factor.ConclusionsPatients transported on V-A ECMO had higher in-hospital mortality, as well as lower 1-year survival. Careful patient selection is required.</p>","PeriodicalId":49707,"journal":{"name":"Perfusion-Uk","volume":" ","pages":"2676591251331952"},"PeriodicalIF":1.1000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcomes of emergency medical service transport on venoarterial extracorporeal life support in cardiogenic shock.\",\"authors\":\"Christine Yang, Iris Feng, Paul Kurlansky, Kathryn Fidlow, Dana A Mullin, Melana Yuzefpolskaya, Paolo C Colombo, Gabriel Sayer, Nir Uriel, Yuji Kaku, Justin Fried, Koji Takeda\",\"doi\":\"10.1177/02676591251331952\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>IntroductionVeno-arterial extracorporeal life support (V-A ECLS) can be utilized to transport cardiogenic shock patients from a regional to a tertiary center. Mobile extracorporeal membrane oxygenation (ECMO) may be life-saving for critically ill patients to bridge to transplant or a higher level of care.MethodsThis study is a retrospective review of adult patients placed on V-A ECMO for cardiogenic shock between 2018 and 2022. Indications and outcomes were compared between patients who were cannulated at referring hospitals and transported via ambulance and those who were placed on VA-ECLS at our institution.Results547 patients with V-A ECMO placed due to cardiogenic shock were included. 94 patients were transported from referring hospitals, while 453 were placed on V-A ECMO at our institution. All were safely transported. In-hospital mortality was significantly higher in transport patients (49.1% vs 59.5%, <i>p</i> = .042). Transport patients had significantly higher rates of acute kidney injury requiring dialysis (27.8% vs 39.4%, <i>p</i>-value = .035) and cerebrovascular accident (6.2% vs 12.8%, <i>p</i>-value = .026). Kaplan-Meier curves showed 6-month survival was significantly lower in transport group (48.5% vs 37.3%, <i>p</i> = .021). Multivariate analysis demonstrated ECMO indication of AMI (OR 1.43, <i>p</i>-value = .037), ECPR (OR 2.45, <i>p</i>-value <.001), and history of COPD (OR 1.55, <i>p</i>-value = .014) were predictors of mortality within 12 months. Notably ECMO transport was not a significant risk factor.ConclusionsPatients transported on V-A ECMO had higher in-hospital mortality, as well as lower 1-year survival. Careful patient selection is required.</p>\",\"PeriodicalId\":49707,\"journal\":{\"name\":\"Perfusion-Uk\",\"volume\":\" \",\"pages\":\"2676591251331952\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-04-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Perfusion-Uk\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/02676591251331952\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Perfusion-Uk","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02676591251331952","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
静脉-动脉体外生命支持(V-A ECLS)可用于将心源性休克患者从区域中心转移到三级中心。移动体外膜氧合(ECMO)可能是挽救危重病人生命的桥梁,以移植或更高水平的护理。方法回顾性分析2018 - 2022年接受V-A ECMO治疗心源性休克的成人患者。在转诊医院插管并通过救护车运送的患者与在我们机构放置VA-ECLS的患者的适应症和结果进行比较。结果纳入547例因心源性休克而行V-A ECMO的患者。94名患者从转诊医院转移,453名患者在我院进行V-A ECMO。所有人都被安全运送。交通患者的住院死亡率明显更高(49.1% vs 59.5%, p = 0.042)。转运患者需要透析的急性肾损伤发生率(27.8% vs 39.4%, p值= 0.035)和脑血管意外发生率(6.2% vs 12.8%, p值= 0.026)显著高于转运患者。Kaplan-Meier曲线显示转运组6个月生存率显著降低(48.5% vs 37.3%, p = 0.021)。多因素分析显示,AMI的ECMO指征(OR 1.43, p值= 0.037)和ECPR (OR 2.45, p值p值= 0.014)是12个月内死亡率的预测因子。值得注意的是,ECMO运输不是显著的危险因素。结论采用V-A型ECMO转运的患者住院死亡率较高,1年生存率较低。需要仔细选择病人。
Outcomes of emergency medical service transport on venoarterial extracorporeal life support in cardiogenic shock.
IntroductionVeno-arterial extracorporeal life support (V-A ECLS) can be utilized to transport cardiogenic shock patients from a regional to a tertiary center. Mobile extracorporeal membrane oxygenation (ECMO) may be life-saving for critically ill patients to bridge to transplant or a higher level of care.MethodsThis study is a retrospective review of adult patients placed on V-A ECMO for cardiogenic shock between 2018 and 2022. Indications and outcomes were compared between patients who were cannulated at referring hospitals and transported via ambulance and those who were placed on VA-ECLS at our institution.Results547 patients with V-A ECMO placed due to cardiogenic shock were included. 94 patients were transported from referring hospitals, while 453 were placed on V-A ECMO at our institution. All were safely transported. In-hospital mortality was significantly higher in transport patients (49.1% vs 59.5%, p = .042). Transport patients had significantly higher rates of acute kidney injury requiring dialysis (27.8% vs 39.4%, p-value = .035) and cerebrovascular accident (6.2% vs 12.8%, p-value = .026). Kaplan-Meier curves showed 6-month survival was significantly lower in transport group (48.5% vs 37.3%, p = .021). Multivariate analysis demonstrated ECMO indication of AMI (OR 1.43, p-value = .037), ECPR (OR 2.45, p-value <.001), and history of COPD (OR 1.55, p-value = .014) were predictors of mortality within 12 months. Notably ECMO transport was not a significant risk factor.ConclusionsPatients transported on V-A ECMO had higher in-hospital mortality, as well as lower 1-year survival. Careful patient selection is required.
期刊介绍:
Perfusion is an ISI-ranked, peer-reviewed scholarly journal, which provides current information on all aspects of perfusion, oxygenation and biocompatibility and their use in modern cardiac surgery. The journal is at the forefront of international research and development and presents an appropriately multidisciplinary approach to perfusion science.